After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...

What’s really exciting about gene editing is precision and speed, says Pairwise cofounder and CEO Tom Adams, PhD.

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...

Learn more about whether Alvotech or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which ...

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and stepped ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne ...

Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should simply ...

Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...